Christine Gennigens

Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

Robert L. Coleman, Domenica Lorusso, Christine Gennigens et al. · The Lancet Oncology · 2021 · 367 citations

Tisotumab Vedotin, Cervical Cancer, Metastatic Cervical Cancer +8

Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

David S. Hong, Nicole Concin, Ignace Vergote et al. · Clinical Cancer Research · 2019 · 122 citations · Full text

Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer

Ignace Vergote, Antonio González‐Martín, Keiichi Fujiwara et al. · New England Journal of Medicine · 2024 · 116 citations · Full text

Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study

Ignace Vergote, Els Van Nieuwenhuysen, Roisin E. O’Cearbhaill et al. · Journal of Clinical Oncology · 2023 · 71 citations · Full text

Randomized Multicenter Phase II Trial Comparing Two Schedules of Etirinotecan Pegol (NKTR-102) in Women With Recurrent Platinum-Resistant/Refractory Epithelial Ovarian Cancer

Ignace Vergote, Agustin A. García, John P. Micha et al. · Journal of Clinical Oncology · 2013 · 52 citations · Full text